J
Jeffrey L. Lennox
Researcher at Emory University
Publications - 95
Citations - 7717
Jeffrey L. Lennox is an academic researcher from Emory University. The author has contributed to research in topics: Viral load & Raltegravir. The author has an hindex of 42, co-authored 94 publications receiving 7236 citations. Previous affiliations of Jeffrey L. Lennox include Grady Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000.
TL;DR: Prolonged survival was associated with receiving therapy that including clarithromycin and receiving combination antiretroviral therapy that included a protease inhibitor and with receiving antimicrobial prophylaxis, but 32 (89%) of 36 patients did not adhere to the proPHylaxis regimen.
Journal ArticleDOI
Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma
TL;DR: The performance characteristics of an enhanced-sensitivity branched-DNA assay (bDNA) and a reverse transcription (RT)-PCR assay (RT-PCR) were compared in a molecular diagnostic laboratory and one non-B subtype was recognized in clinical specimens based on the ratio of values obtained with the two methods.
Journal ArticleDOI
Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection
Ighovwerha Ofotokun,Kehmia Titanji,Aswani Vunnava,Susanne Roser-Page,Tatyana Vikulina,Francois Villinger,Kenneth A. Rogers,Anandi N. Sheth,Cecile D. Lahiri,Jeffrey L. Lennox,M. Neale Weitzmann +10 more
TL;DR: The data suggest that ART-induced bone loss occurs early, is aligned with early events of immune reconstitution, and these immune changes provide a unifying mechanism to explain in part the skeletal decline common to all ART.
Journal ArticleDOI
Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257
Ighovwerha Ofotokun,Lumine H. Na,Raphael J. Landovitz,Heather J. Ribaudo,Grace A. McComsey,Catherine Godfrey,Francesca T. Aweeka,Susan E. Cohn,Manish Sagar,Daniel R. Kuritzkes,Todd T. Brown,Kristine B. Patterson,Michael F. Para,Randi Y. Leavitt,Angelina Villasis-Keever,Bryan Baugh,Jeffrey L. Lennox,Judith S. Currier +17 more
TL;DR: Ritonavir C24 was not different in the PI arms and had no relationship with the modest but comparable increases in lipids observed with either atazanavir or darunavir, and raltegravir produced the most favorable lipid profile.
Journal ArticleDOI
Prospective study of etiologic agents of community-acquired pneumonia in patients with Hiv infection
David Rimland,Thomas R. Navin,Jeffrey L. Lennox,J A Jernigan,Jonathan E. Kaplan,D Erdman,C J Morrison,S P Wahlquist +7 more
TL;DR: Despite the use of extensive testing, a definite etiology in a large number of cases of pneumonia was not found and the rarity of ‘atypical agents’ could simplify the empiric approach to therapy.